Prevalence and associated risk factors of early morning off among the patients with Parkinson’s disease in China
Objective: To explore the prevalence and associated risk factors of early morning off (EMO) among outpatients with Parkinson’s disease (PD) in China. Background: PD is…Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study
Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients
Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment
Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…Tremor and parkinsonism in Chromosomopathies – a systematic review
Objective: To review the co-occurrence of parkinsonism and tremor syndromes in patients with chromosomic disorders. Background: The landscape of genetic forms of Parkinson’s diseases (PD)…The potential modifier effect of C9orf72 DNA methylation in C9ORF72 carriers
Objective: To develop molecular assays for determining the influence of hypermethylation on age of onset for C9ORF72 carriers. Background: Hexanucleotide repeats of GGGGCC in C9ORF72 is…Serum MIR-96-5P and MIR-339-5P as a Potential Biomarker for Multiple System Atrophy and Parkinson’s Disease
Objective: The aim of our study was to to determine if serum mir-96-5p and mir-339-5p can be used as biomarkers for early diagnosis of Parkinson’s…Hypophosphatasia presenting as parkinsonism with compound heterozygous mutations in ALPL gene
Objective: We report a hypophosphatasia patient presenting as parkinsonism, characterized by compound heterozygous mutations in ALPL gene. Background: Hypophosphatasia (HPP) is a rare metabolism disease,…Correlation Between Drooling and Quality of Life in Parkinson’s Disease
Objective: The aim of this study was to evaluate the relationship between the quality of life and drooling in Parkinson’s disease patients. Background: Parkinson’s disease…
- « Previous Page
- 1
- …
- 223
- 224
- 225
- 226
- 227
- …
- 425
- Next Page »